Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Elife|February 27, 2016
Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-atrophic ubiquitin ligase Trim63Yannick von Grabowiecki, Paula Abreu, Orphee Blanchard, et al.
Journal of Inorganic Biochemistry|October 9, 2025
Evaluation of dual-function molecules containing both Zn-Ionophore and aggregation inhibition moieties for mutant p53 protein reactivationKalvin Kwan, Ashkan Saffari, Lauryn Grcic, et al.
Cancers|November 10, 2019
HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK PathwayMarie-Elodie Spaety, Alexandre Gries, Amandine Badie, et al.
Oncotarget|December 10, 2016
A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatinCynthia Licona, Marie-Elodie Spaety, Antonelle Capuozzo, et al.
Journal of Inorganic Biochemistry|March 5, 2023
Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220CJessica J Miller, Kalvin Kwan, Anaïs Blanchet, et al.
Oncogene|November 14, 2020
The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanismsMarine Beck, Mathilde Baranger, Ahlam Moufok-Sadoun, et al.
The Journal of Cell Biology|March 9, 2011
Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epitheliumFrançois Gerbe, Johan H van Es, Leila Makrini, et al.
Cancer Letters|January 30, 2024
The unfolded protein response-glutathione metabolism axis: A novel target of a cycloruthenated complexes bypassing tumor resistance mechanismsGilles Riegel, Christophe Orvain, Sevda Recberlik, et al.
Biochemical Pharmacology|September 12, 2012
Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicityVania Vidimar, Xiangjun Meng, Marcelina Klajner, et al.
Cancer Letters|October 20, 2018
A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53Vania Vidimar, Cynthia Licona, Ricardo Cerón-Camacho, et al.
Pageof 4